{
    "clinical_study": {
        "@rank": "136361", 
        "arm_group": [
            {
                "arm_group_label": "chemotherapy group(B)", 
                "arm_group_type": "Experimental", 
                "description": "received the same chemotherapy regimen alone every 4 weeks for up to six cycles, then continued to receive pemetrexed alone every 4 weeks"
            }, 
            {
                "arm_group_label": "combination therapy group(A)", 
                "arm_group_type": "Experimental", 
                "description": "pemetrexed (500 mg/m(2) on day 1) plus carboplatin (AUC 5 on day 1) combined with gefitinib (250 mg/day on days 5-21) and repeated every 4 weeks for up to six cycles,"
            }, 
            {
                "arm_group_label": "gefitinib group (group C)", 
                "arm_group_type": "Experimental", 
                "description": "received gefitinib alone. All therapies of 3 groups were continued until progression or unacceptable toxicity or death"
            }
        ], 
        "brief_summary": {
            "textblock": "The results of fastact2 show that chemotherapy plus erlotinib significantly prolonged PFS\n      and OS of patients with NSCLC. However, outcome of the combination therapy are similar to\n      those reported in several trials of single-agent EGFR TKIs. So which is the optimal\n      first-line treatment for patients who harbored a sensitive EGFR mutation? The investigators\n      need a head-to-head study to reply."
        }, 
        "brief_title": "Combination of Chemotherapy and Gefitinib as First-line Treatment of Patients With Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomised Controlled Trial", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Non-Small-Cell Lung", 
            "Erlotinib"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Signed informed consent\n\n          2. Age >=18 years\n\n          3. Histologically documented, unresectable, inoperable, locally advanced, recurrent or\n             metastatic  Stage IV Non-Small Cell Lung Cancer (NSCLC)\n\n          4. A cytologic diagnosis is acceptable (i.e., FNA or pleural fluid cytology)\n\n          5. Measurable or non-measurable disease\n\n          6. Able to comply with study and follow-up procedures\n\n        Exclusion Criteria:\n\n          -  Evidence of small cell, carcinoid, or mixed small cell/non-small cell histology\n\n          -  Malignancies within 3 years except for adequately treated carcinoma in situ of -the\n             cervix or basal or squamous cell skin cancer\n\n          -  Symptomatic or untreated brain metastases\n\n          -  Prior systemic chemotherapy for NSCLC\n\n          -  Unstable systemic disease, including active infection, uncontrolled hypertension,\n             unstable angina, congestive heart failure, or myocardial infarction within 6 months\n             prior to Day 1, or serious cardiac arrhythmia requiring medication (patients with\n             chronic atrial arrhythmia, i.e., atrial fibrillation or paroxysmal supraventricular\n             tachycardia, are eligible)\n\n          -  History of other diseases, metabolic dysfunction, physical examination finding, or\n             clinical laboratory finding giving reasonable suspicion of a disease or condition\n             that contraindicates the use of an investigational drug or that might affect the\n             interpretation of the results of the study or render the patient at high risk from\n             treatment complications\n\n          -  Gastrointestinal tract disease resulting in an inability to take oral medication or a\n             requirement for intravenous (IV) alimentation, or prior surgical procedures affecting\n             absorption\n\n          -  Pregnancy or lactation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02148380", 
            "org_study_id": "chest20140001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "chemotherapy group(B)", 
                    "combination therapy group(A)"
                ], 
                "intervention_name": "pemetrexed  plus carboplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "combination therapy group(A)", 
                    "gefitinib group (group C)"
                ], 
                "intervention_name": "gefitinib", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Pemetrexed", 
                "Gefitinib", 
                "Carboplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 28, 2014", 
        "location": {
            "contact": {
                "email": "xkywk@126.com", 
                "last_name": "Baohui Han, Dr.", 
                "phone": "+86 13817833343"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "zip": "200030"
                }, 
                "name": "Shanghai Chest Hospital"
            }, 
            "investigator": {
                "last_name": "Bohui Han, Dr.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "3", 
        "official_title": "Combination of Chemotherapy and Gefitinib as First-line Treatment of Patients With Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomised Controlled Trial", 
        "overall_contact": {
            "email": "lj991117@163.com", 
            "last_name": "Bo Jin, Dr", 
            "phone": "+86 13761872187"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Science and Technology Commission of Shanghai Municipality:China", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "progression-free survival", 
            "safety_issue": "No", 
            "time_frame": "6-month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02148380"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shanghai Chest Hospital", 
            "investigator_full_name": "Bo Jin", 
            "investigator_title": "associate chief physician", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "overall survival", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Toxicity will be graded according to NCI CTCAE, version 4.0. The analysis of safety/tolerability data will be descriptive; toxicity events will be individually tabulated.", 
                "measure": "to evaluate the safety profile between three groups", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Shanghai Chest Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bo Jin", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}